The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Britain summons EU diplomat over accusation it banned COVID-19 vaccine exports

Wed, 10th Mar 2021 11:22

* Johnson denies Britain has banned exports

* EU says Britain uses AstraZeneca contract to block
shipments

* Relations sour post-Brexit
(Adds spokesman, Lewis comments)

By Gabriela Baczynska, Philip Blenkinsop and Elizabeth Piper

BRUSSELS/LONDON, March 10 (Reuters) - Britain denied an
accusation on Wedneday by the European Union that it had banned
exports of COVID-19 vaccines, and summoned an EU diplomat to
complain.

Britain, which quit the EU last year, has provided vaccine
doses to more than a third of its population, far outpacing the
27 remaining EU members.

They, in turn, have been casting blame on drug companies for
failing to meet delivery targets, including AstraZeneca, which
makes COVID-19 vaccines both in Britain and the EU and has
declined to divert British doses to the bloc to meet a shortfall
there.

The EU says it has allowed millions of doses of Pfizer
vaccines, which Britain does not make, to be exported there. On
Tuesday, European Council President Charles Michel said Britain,
like the United States, had "outright" banned exports of
vaccines produced on its territory.

London says it has no such ban, and credits the success of
its vaccine programme to strong negotiations with drug companies
last year and early investment in supply chains. EU officials
say London has effectively prevented exports of AstraZeneca
vaccines by invoking a clause in its contract that
requires the company to fulfil Britain's order first.

British Prime Minister Boris Johnson told parliament he had
to "correct" Michel's suggestion. His government had "not
blocked the export of any single COVID-19 vaccine or vaccine
components", he said.

The foreign office said it had summoned EU charge d'affaires
Nicole Mannion "to discuss the issue of incorrect assertions in
recent EU communications".

Asked whether Britain was using its AstraZeneca contract to
effectively block exports, a spokesman for Johnson said: "The
movement of vaccines and their components into and out of the UK
is driven by contractual obligations that vaccine suppliers have
to their customers."

After initially saying Britain had imposed an "outright"
export ban, Michel later said there were "different ways of
imposing bans or restrictions on vaccines".

An EU official said the bloc had allowed exports of 8
million doses of COVID-19 vaccines to Britain since Jan. 30, and
many more earlier. Manfred Weber, head of the largest political
group in the European Parliament, told Britain's foreign
secretary to "stop lecturing and to show Britain's export data."

The vaccine dispute comes at a time when the bloc and its
former member are also quarrelling over Brexit. An EU diplomat
said such verbal jousting was "the new normal".

"With more economic divergence and more competition ahead,
pressure on our Brexit agreements will only grow," the diplomat
said.

Last week, Britain unilaterally extended a grace period on
checks of food arriving in Northern Ireland from other parts of
the United Kingdom, required under its Brexit deal. The move is
expected to prompt a legal challenge from Brussels this week,
two Brussels diplomatic sources said.

"This was another provocation. It's not the first, and
nobody expects it to be the last. The EU will keep calm and
react firmly," said a second senior EU diplomat.
(Reporting by Philip Blenkinsop, Gabriela Baczynska, Francesco
Guarascio, and Sarah Young and Elizabeth Piper in London;
Editing by Alex Richardson and Hugh Lawson)

More News
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.